Anglo-Swedish drug major AstraZeneca says that data published in the American Heart Journal show that Atacand (candesartan cilexetil), its anti-hypertension drug, when added to contemporary therapy significantly, reduced the incidence of atrial fibrillation in a wide range of heart failure patients, including those with reserved as well as reduced left ventricular systolic function. AF, the incidence of which increases 10%-30% following heart failure, is associated with a decline in cardiac function and worsening of symptoms. Atacand is approved in over 60 countries worldwide.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze